OSE Immunotherapeutics Overview
Pro stress-test →OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and immuno-inflammation. The company's lead assets, lusvertikimab and Tedopi®, hold the potential to redefine standards of care across multiple diseases in immuno-inflammation and immuno-oncology.
Strategic Profile
Pro stress-test →As of March 2026, the company has announced a targeted realignment of its R&D portfolio, pausing development of OSE-230 to focus resources on late-stage, high-potential assets lusvertikimab and Tedopi®. These two assets are expected to generate multiple clinical catalysts over the next three years. The company continues to explore various options, including business development, strategic alliances, international investments, and a potential Nasdaq listing.
Competitive Landscape
Pro stress-test →OSE competes with biotech firms including Innate Pharma, Immatics, ImmunityBio, Aura Biosciences, and Transgene. OSE differentiates through proprietary immune-modulation platforms targeting both immune activation (immuno-oncology) and suppression (immuno-inflammation), with clinical programs in late-stage development backed by European partnerships.
Industry Context
OSE Immunotherapeutics operates in Biotechnology - Clinical-stage immunotherapies (Immuno-Oncology and Immuno-Inflammation).
Key facts
Founded: 2016 · Headquarters: Nantes, France · Employees: 65 · Revenue: $2.31M · Market cap: $162M